Interindividual Variations in Drug Disposition. Clinical Implications and Methods of Investigation

Overview

Journal Clin Pharmacokinet

Specialty Pharmacology

Date 1983 Sep 1

PMID 6627809

Citations 41

Authors

D D Breimer

Affiliations

Soon will be listed here.

Citing Articles

Effects of salidroside on rat CYP enzymes by a cocktail of probe drugs.

Wei Y, Du H, Lin Y, Wu M, Xu R Iran J Basic Med Sci. 2018; 21(4):422-426.

PMID: 29796228 PMC: 5960761. DOI: 10.22038/IJBMS.2018.26106.6414.

Evaluation of CYP2C9 Activity in Rats: Use of Tolbutamide Alone and in Combined with Bupropion.

Qiu X, Song J, Yuan H, Hou Y, Pan X, Xu R Iran J Pharm Res. 2014; 13(2):635-9.

PMID: 25237359 PMC: 4157039.

Correlation between in vivo antipyrine metabolite formation and theophylline metabolism in rats.

Teunissen M, Brorens I, De Langen H, Geerlings A, Breimer D Pharm Res. 2013; 3(3):156-61.

PMID: 24271521 DOI: 10.1023/A:1016361907787.

Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Kerbusch T, de Kraker J, Keizer H, Van Putten J, Groen H, Jansen R Clin Pharmacokinet. 2001; 40(1):41-62.

PMID: 11236809 DOI: 10.2165/00003088-200140010-00004.

Effect of tacrine hydrochloride on hepatic drug metabolism.

Danbury T, Eccles M, Ford J, Roberts C Eur J Drug Metab Pharmacokinet. 1999; 24(1):91-6.

PMID: 10412897 DOI: 10.1007/BF03190016.

References

Vesell E . The antipyrine test in clinical pharmacology: conceptions and misconceptions. Clin Pharmacol Ther. 1979; 26(3):275-86. DOI: 10.1002/cpt1979263275. View

Vesell E, Penno M . Assessment of methods to identify sources of interindividual pharmacokinetic variations. Clin Pharmacokinet. 1983; 8(5):378-409. DOI: 10.2165/00003088-198308050-00002. View

Greenblatt D, Divoll M, Abernethy D, Harmatz J, Shader R . Antipyrine kinetics in the elderly: prediction of age-related changes in benzodiazepine oxidizing capacity. J Pharmacol Exp Ther. 1982; 220(1):120-6. View

Van den Broek J, Teunissen M, Breimer D . Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig. Drug Metab Dispos. 1981; 9(6):541-4. View

Danhof M, Teunissen M, Breimer D . 3-Hydroxymethyl antipyrine excretion in urine after an oral dose of antipyrine. A reconsideration of previously published data and synthesis of a pure reference substance. Pharmacology. 1982; 24(3):181-4. DOI: 10.1159/000137594. View

Boobis A, Brodie M, Kahn G, Toverud E, Blair I, Murray S . Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man. Br J Clin Pharmacol. 1981; 12(6):771-7. PMC: 1401933. DOI: 10.1111/j.1365-2125.1981.tb01305.x. View

Penno M, Dvorchik B, Vesell E . Genetic variation in rates of antipyrine metabolite formation: a study in uninduced twins. Proc Natl Acad Sci U S A. 1981; 78(8):5193-6. PMC: 320370. DOI: 10.1073/pnas.78.8.5193. View

Idle J, Smith R . Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979; 9(2):301-17. DOI: 10.3109/03602537908993896. View

KALOW W . Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982; 7(5):373-400. DOI: 10.2165/00003088-198207050-00001. View

10.

Mellstrom B, Bertilsson L, Sawe J, Schulz H, Sjoqvist F . E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther. 1981; 30(2):189-93. DOI: 10.1038/clpt.1981.147. View

11.

Eichelbaum M . Defective oxidation of drugs: pharmacokinetic and therapeutic implications. Clin Pharmacokinet. 1982; 7(1):1-22. DOI: 10.2165/00003088-198207010-00001. View

12.

Alvan G . Individual differences in the disposition of drugs metabolised in the body. Clin Pharmacokinet. 1978; 3(2):155-75. DOI: 10.2165/00003088-197803020-00005. View

13.

Fraser H, Mucklow J, Bulpitt C, Khan C, Mould G, Dollery C . Environmental effects on antipyrine half-life in man. Clin Pharmacol Ther. 1977; 22(5 Pt 2):799-808. DOI: 10.1002/cpt1977225part2799. View

14.

Fraser H, Mucklow J, Bulpitt C, Kahn C, Mould G, Dollery C . Environmental factors affecting antipyrine metabolism in London factory and office workers. Br J Clin Pharmacol. 1979; 7(3):237-43. PMC: 1429487. DOI: 10.1111/j.1365-2125.1979.tb00928.x. View

15.

Toverud E, Boobis A, Brodie M, Murray S, Bennett P, Whitmarsh V . Differential induction of antipyrine metabolism by rifampicin. Eur J Clin Pharmacol. 1981; 21(2):155-60. DOI: 10.1007/BF00637517. View

16.

Alvares A, Kappas A, Eiseman J, Anderson K, Pantuck C, PANTUCK E . Intraindividual variation in drug disposition. Clin Pharmacol Ther. 1979; 26(4):407-19. DOI: 10.1002/cpt1979264407. View

17.

Danhof M, Breimer D . Assay of antipyrine and its primary metabolites in plasma, saliva and urine by high-performance liquid chromatography and some preliminary results in man. Pharmacology. 1979; 18(4):210-23. DOI: 10.1159/000137254. View

18.

Blain P, Mucklow J, Wood P, Roberts D, Rawlins M . Family study of antipyrine clearance. Br Med J (Clin Res Ed). 1982; 284(6310):150-2. PMC: 1495529. DOI: 10.1136/bmj.284.6310.150. View

19.

Sjoqvist F, von Bahr C . Interindividual differences in drug oxidation: clinical importance. Drug Metab Dispos. 1973; 1(1):469-82. View

20.

Jusko W, Gardner M, Mangione A, Schentag J, Koup J, VANCE J . Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci. 1979; 68(11):1358-66. DOI: 10.1002/jps.2600681106. View